Fludarabine/i.v. BU conditioning regimen: Myeloablative, reduced intensity or both?

Bone Marrow Transplantation

Volumn 41, Issue 11, 2008, Pages 935-940

  Chunduri, S ^a   Dobogai, L C ^a   Peace, D ^a   Saunthararajah, Y ^a   Quigley, J ^a   Chen, Y H ^a   Mahmud, N ^a   Hurter, E ^a   Beri, R ^a   Rondelli, Drond ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; FLUDARABINE; METHOTREXATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADD ON THERAPY; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW DISEASE; CANCER RELAPSE; CANCER RISK; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HLA MATCHING; HUMAN; LYMPHOMA; MALE; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SURVIVAL RATE;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; BUSULFAN; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 45449093051     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.13     Document Type: Article

References (29)

1. Taylor PR, Reid MM, Stark AN, Bown N, Hamilton PJ, Proctor SJ, Northern Region Haematology Group. De novo acute myeloid leukaemia in patients over 55-years-old: A population-based study of incidence treatment and outcome. Leukemia 1995; 9: 231-237.
2. Martino R, Guardia R, Altes A. Sureda A, Brunet S, Sierra J. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: Results of the phase II Gemia protocol. Haematologica 1999; 84: 226-230.
3. Leopold LH. Willemze R. The treatment of acute myeloid leukemia in first relapse: A comprehensive review of the literature. Leuk Lymphoma 2002: 43: 1715-1727.
4. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML. Chen IM et al Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997: 89: 1323-3329.
5. Thomas E. Storb R, Clift RA. Fefer A. Johnson FL, Neiman PE et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975; 292: 832-843.
6. Barrett AJ. Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: A review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006; 20: 1661-1672.
7. Bacigalupo A. Vitale V, Corvo R, Barra S. Lamparelli T. Gualandi F et al. The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients acute myeloid leukaemia undergoing allogeneic bone marrow transplantation. Br J Haematol 2000; 108: 99-104.
8. Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C et al Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468-476.
9. Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003; 102: 820-826.
10. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R et al. Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857-864.
11. McDonald GB, Slattery JT. Bouvier ME, Ren S, Batchelder AL, Kalhorn TF et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101: 2043-2048.
12. Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Chen HY, Mahmud N et al. Comparable kinetics of myeloablation between fludarabine/ full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 38: 477-482.
13. Bonifazi F, Bandini G, Rondelli D, Falcioni S, Stanzani M, Bontadini A et al. Reduced incidence of GVHD without increase in relapse with low-dose rabbit ATG in the preparative regimen for unrelated bone marrow transplants in CML. Bone Marrow Transplant 2003; 32; 237-242.
14. Bonifazi F, Bandini G, Stanzani M, Palandri F, Giannini B, Arpinati M et al. In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: Results from a prospective phase 11 study. Bone Marrow Transplant 2005; 35: 1025-1026.
15. Thiede C, Florek M, Bornhauser M, Ritter M, Mohr B, Brendel C et al Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999; 23: 1055-1060.
16. Przepiorka D. Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
17. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991: 28: 250-259.
18. Byrd JC. Mrozek K, Dodge RK. Carroll AJ. Edwards CG, Arthur DC et al Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002: 100: 4325-4336.
19. Jurado M, Deeg HJ, Storer B, Anasetti C, Anderson JE, Bryant E et al Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable non-relapse mortality. Biol Blood Marrow Transplant 2002; 8: 161-169.
20. Geller RB, Devine SM, O'Toole K, Persons L, Keller J, Mauer D et al Allogeneic bone marrow transplantation with matched Unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated total body irradiation. Bone Marrow Transplant 1997; 20: 219-225.
21. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347-1353.
22. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
23. Wallen H, Gooley TA, Deeg HJ, Pagel JM, Press OW, Appelbaum FR et al Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 2005; 23: 3439-3446.
24. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelo-dysplasia. J Clin Oncol 2005; 23: 9387-9393.
25. Popat U, Heslop HE, Durett A, May R, Krance RA, Brenner MK et al. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplant 2006; 37: 547-552.
26. Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients With myelofibrosis with myeloid metaplasia. Blood 2005; 105: 4115-4119.
27. Shimom A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: The role of dose intensity. Leukemia 2006; 20: 322-328.
28. Russell JA. Turner AR, Larratt L. Chaudhry A. Morris D. Brown C et al Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: A matched pair analysis. Biol Blood Marrow Transplant 2007; 13 299-306.
29. Bacigalupo A, Lamparelli T. Barisione G, Bruzzi P. Guidi S, Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: Long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006, 12: 560-565.